stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. LIMN
    stockgist
    HomeTop MoversCompaniesConcepts
    LIMN logo

    Iris Acquisition Corp

    LIMN
    NASDAQ
    Healthcare
    Biotechnology
    La Palma, CA, US3 employeesliminatuspharma.com
    $0.17
    +0.00(1.87%)

    Mkt Cap $5M

    $0.17
    $26.67

    52-Week Range

    At A Glance

    1

    Liminatus Pharma, Inc.

    2

    No significant events in the past 90 days.

    $5M

    Market Cap

    —

    Revenue

    -$3M

    Net Income

    Employees3
    Fundamentals

    How The Business Makes Money

    Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.

    Industry Biotechnology
    Activity

    What Changed Recently

    No significant events in the past 90 days.

    Peer Companies

    CompanyPriceChangeMarket CapP/E
    MAIAMAIA Biotechnology, Inc.$1.34-0.37%$52M—
    SABSSAB Biotherapeutics, Inc.$3.88+0.13%$37M5.7
    GBIOGBIO$5.34+0.00%$36M—
    MURAMURA$2.04+0.00%$35M—
    DYAIDyadic International, Inc...$0.91+6.44%$33M-4.0
    ATHEAlterity Therapeutics Lim...$3.56-2.22%$32M-5.6
    BTAIBioXcel Therapeutics, Inc...$1.18-3.69%$29M-0.3
    EVAXEvaxion Biotech A/S$3.74-5.08%$24M-3.2
    Company Profile
    CIK0001831874
    ISINUS53271X1081
    Address6 Centerpointe Drive, La Palma, CA, 90623, US
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice